Review



biotinylated cd9  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Novus Biologicals biotinylated cd9
    Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of <t>CD9,</t> alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .
    Biotinylated Cd9, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd9+antibody+%28mem-61%29+biotin/pmc12832073-156-21-23?v=Novus+Biologicals
    Average 92 stars, based on 2 article reviews
    biotinylated cd9 - by Bioz Stars, 2026-08
    92/100 stars

    Images

    1) Product Images from "Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance"

    Article Title: Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance

    Journal: Journal of Extracellular Vesicles

    doi: 10.1002/jev2.70219

    Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of CD9, alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .
    Figure Legend Snippet: Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of CD9, alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .

    Techniques Used: Mass Spectrometry, Mutagenesis, Isolation, Cell Culture, Concentration Assay, Western Blot, Expressing, Software



    Similar Products

    anti cd9 mem 61  (Bio-Techne corporation)
    91
    Bio-Techne corporation anti cd9 mem 61
    Anti Cd9 Mem 61, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd9+antibody+%28mem-61%29+biotin/pm36805937-63-0-17?v=Bio-Techne+corporation
    Average 91 stars, based on 1 article reviews
    anti cd9 mem 61 - by Bioz Stars, 2026-08
    91/100 stars
    		  Buy from Supplier
    biotinylated cd9  (Novus Biologicals)
    92
    Novus Biologicals biotinylated cd9
    Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of <t>CD9,</t> alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .
    Biotinylated Cd9, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd9+antibody+%28mem-61%29+biotin/pmc12832073-156-21-23?v=Novus+Biologicals
    Average 92 stars, based on 1 article reviews
    biotinylated cd9 - by Bioz Stars, 2026-08
    92/100 stars
    		  Buy from Supplier
    cd9 antibody (mem-61) biotin  (Novus Biologicals)
    90
    Novus Biologicals cd9 antibody (mem-61) biotin
    Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of <t>CD9,</t> alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .
    Cd9 Antibody (Mem 61) Biotin, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd9+antibody+%28mem-61%29+biotin/us12117440-248-10-16?v=Novus+Biologicals
    Average 90 stars, based on 1 article reviews
    cd9 antibody (mem-61) biotin - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    anti cd9 antibody mem 61  (Novus Biologicals)
    91
    Novus Biologicals anti cd9 antibody mem 61
    Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of <t>CD9,</t> alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .
    Anti Cd9 Antibody Mem 61, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd9+antibody+%28mem-61%29+biotin/pmc08447189-46-0-9?v=Novus+Biologicals
    Average 91 stars, based on 1 article reviews
    anti cd9 antibody mem 61 - by Bioz Stars, 2026-08
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of CD9, alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .

    Journal: Journal of Extracellular Vesicles

    Article Title: Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance

    doi: 10.1002/jev2.70219

    Figure Lengend Snippet: Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of CD9, alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .

    Article Snippet: Briefly, coverslips were incubated with 1 μg/μL silane‐PEG‐Biotin (Laysian Bio, Inc., AL, USA, cat. #145‐40), blocked with casein and conjugated with biotinylated CD9 (Novus Biologicals, Abingdon, United Kingdom, cat. #NB500‐327B) using a streptavidin linker.

    Techniques: Mass Spectrometry, Mutagenesis, Isolation, Cell Culture, Concentration Assay, Western Blot, Expressing, Software